Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 22, 2000

View Archived Issues

BioPulse and Brigham Young partner on major cancer diagnostic breakthrough

PathoGenome database utilized for antiinfective drug discovery

Eisai responsible for Japanese development, marketing of botulinum toxin type B

Conformationally constrained butyrophenones as potential antipsychotic agents

Cellegy begins expanded phase I/II trial with Tostrelle; new collaboration on FSD announced

Alza licenses dapoxetine from PPD GenuPro

Ranolazine enters phase II for CHF

Apthera for canker sores approved in Canada

Phenserine enters phase II trial for Alzheimer's disease

Anti-IL-9 antibody collaboration terminated by Genentech

York Medical changes name, reports pipeline progress

VX-148 enters clinical development

Potent, selective proteasome compounds derived from belactosin

Mitsubishi-Tokyo stops development of antidepressant MCI-225

Development of MKC-542 under consideration at Mitsubishi-Tokyo

TKT reacquires rights to second Gene-Activated Protein from Aventis

Preclinical trials with decitabine suggest potential in myelodysplastic syndrome, multiple myeloma

Schering-Plough to market pranlukast in Latin America

Potential of tegaserod in GERD therapy indicated by recent clinical study findings

Spanish researchers claim novel antiviral agents

Taisho presents new compounds with potential in the treatment of renal and cardiovascular conditions

Pyrazole derivatives from Yamanouchi inhibit CRACC and IL-2 production

Recent patent covers new GnRH antagonists prepared by Merck scientists

Prostaglandin analogues for glaucoma, ocular hypertension described in December patent

New oncolytic drugs from Schering-Plough act by inhibiting protein farnesyltransferase

Dual inhibitors of ACE/NEP in development at Toa Eiyo

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...